1. Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer
- Author
-
Lili Mi, Ning Li, Huacun Shi, Cuizhen Li, Guangjie Han, Baoen Shan, Fei Yin, and Jianfei Shi
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Tegafur ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Neoplasm Metastasis ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Liposome ,Chemotherapy ,business.industry ,Cancer ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Paclitaxel Liposome ,Oxaliplatin ,Treatment Outcome ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Liposomes ,Female ,Liver function ,business ,Biomarkers ,Follow-Up Studies ,medicine.drug - Abstract
Aim: To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients. Materials & methods: Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death. Results: Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor. Conclusion: First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.
- Published
- 2019